Chaoju Eye Care Holdings Limited 2025 Annual Report: Key Investor Insights

Highlights from the 2025 Annual Report

• Robust Operational Strategy: The Group maintained steady development in 2025, adhering to strategic objectives with a strong focus on cost management and resource allocation, despite market fluctuations.
• Significant Dividend Increase: The Board has recommended a final dividend of HK\$0.2423 per Share for 2025, more than double the prior year’s HK\$0.1193 per Share. This is a key positive for investors, indicating strong cash flow and management confidence.
• Cash-Rich Position: As of December 31, 2025, the Group remains in a net cash position, with no gearing ratio applicable. Cash and cash equivalents at year-end were RMB 516.3 million.
• Large-Scale Wealth Management Investments: The Group maintained a portfolio of wealth management products with a total outstanding principal of RMB 190.0 million, representing 6.3% of total assets and generating RMB 9.9 million in fair value gains.
• Revenue Diversification & Expansion: Continued strategy to expand both hospital networks and consumer ophthalmic market, leveraging clinical expertise and brand strength.
• Major Supplier Concentration: The Group’s five largest suppliers accounted for 61.37% of total purchases, with the largest single supplier representing 22.68%—a potential risk and negotiation leverage point.
• Share Buybacks: The Company repurchased and cancelled a total of 1,850,000 shares in 2025, and an additional 2,330,000 shares between November 2025 and January 2026, signaling confidence in undervaluation and shareholder value focus.
• Risk Management & Corporate Governance: Robust internal controls, risk management, and compliance with all material environmental and legal obligations. No major disputes, litigation, or regulatory breaches reported.
• Potential Regulatory and Structural Risks: The Group utilizes contractual arrangements in the PRC for certain operations, which are subject to regulatory uncertainty and possible scrutiny. Any change in regulatory stance may impact the Group’s operational structure and financial results.
• Substantial Shareholder Concentration: The controlling shareholders (Mr. Zhang Bozhou, Ms. Zhang Xiaoli, Mr. Zhang Junfeng, and others) collectively hold over 40% of the company, aligning management and shareholder interests but also concentrating voting power.
• ESG Commitment: The Group continues to invest in environmental, social, and governance initiatives, including employee training, community donations (RMB 3.4 million in 2025), and environmental compliance.

Details Investors Should Watch

1. Dividend and Capital Management

The proposed final dividend of HK\$0.2423 per Share for 2025, subject to shareholder approval, is noteworthy for its substantial increase year-on-year. The payout reflects robust financial health and management’s confidence in sustainable profit generation. The expected payment date is June 3, 2026, to shareholders on record as of May 20, 2026.

The Company remains in a net cash position, providing flexibility for future investments, buybacks, or increased returns to shareholders.

2. Wealth Management Products

As of year-end, the Group held RMB 190 million in wealth management products, earning RMB 9.9 million in fair value gains. This represents 6.3% of total assets and indicates active treasury management. Management asserts these products are low-risk and provide higher yields than bank deposits, but investors should remain aware of potential liquidity and counterparty risks.

3. Risk Factors and Regulatory Issues

Regulatory Uncertainty: The Group’s use of contractual arrangements (VIE structures) to control certain PRC operations could be subject to regulatory changes or enforcement actions in China. Any adverse regulatory development could materially impact the Group’s control over its key assets and income streams. This remains a major sensitivity for share valuation.

Supplier Concentration Risk: The reliance on a small group of suppliers for over 60% of total purchases may affect procurement costs and supply chain stability. Any disruption or renegotiation could have a direct impact on margins.

4. Share Buybacks

The repurchase and cancellation of 1,850,000 shares during 2025, and an additional 2,330,000 shares shortly after year-end, underscores management’s commitment to supporting the share price and enhancing shareholder value. Repurchases were executed at prices ranging from HK\$2.53 to HK\$2.75 per share.

5. Expansion and Use of IPO Proceeds

The Company raised approximately HK\$1.599 billion from its July 2021 IPO, with significant proceeds allocated to new hospital establishments, acquisitions, and IT upgrades. As of August 29, 2025, HK\$533.35 million remained unutilized, with full deployment expected by December 31, 2027.

6. Financial Performance and Earnings

Net profit attributable to shareholders for 2025 was RMB 183.4 million. Basic earnings per share stood at RMB 0.26, with a weighted average of 693.6 million shares in issue. The company’s asset-liability ratio remains low at 20%.

7. Other Notable Points

• No significant or material disputes with stakeholders during the year.
• Directors and management have no material competing business interests.
• No major acquisitions or disposals in 2025.
• No material legal proceedings or regulatory non-compliance was reported.

Potential Share Price Sensitivities

• The sharp increase in dividend payout and ongoing share buybacks will likely be viewed positively by investors, potentially supporting the stock price.
• The Group’s strong net cash position and prudent capital allocation provide flexibility and are attractive in the current market environment.
• Ongoing regulatory uncertainty regarding the Group’s contractual arrangements in the PRC remains a significant risk and could lead to share price volatility if policy changes arise.
• Significant supplier concentration may be a risk factor to monitor, particularly in the context of supply chain disruptions or pricing pressures.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult their financial advisor before making investment decisions. The information herein is based on the 2025 Annual Report of Chaoju Eye Care Holdings Limited and is believed to be accurate at the time of writing, but no warranty is given as to its accuracy or completeness. The author and publisher accept no liability for any direct or consequential loss arising from any use of this information.

View CHAOJU EYE CARE Historical chart here